Investor Relations Home
Check-Cap is redefining colorectal cancer (CRC) screening and prevention through the introduction of C-Scan®, the first and only patient-friendly preparation-free test to detect polyps before they may transform into cancer. The company’s disruptive capsule-based screening technology aims to drastically increase screening adherence worldwide and help millions of people stay healthy through preventive CRC screening. The technology has been evaluated in a pilot study in the U.S. and has received regulatory approval for marketing in the EU and Israel. Data from clinical trials showed promising results, including safety, high patient compliance, and high sensitivity at detecting precancerous polyps when the technology was compared to the FIT test.
The C-Scan System utilizes an ultra-low dose X-ray capsule, an integrated positioning, control, and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. C-Scan is patient-friendly and requires no preparation or sedation, allowing the patients to continue their daily routine with no interruption as the capsule is propelled through the gastrointestinal tract by natural motility.